Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Bevacizumab
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
July 11, 2024
Lead Product(s) : Bevacizumab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sulfur Hexafluoride
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : NaviFUS
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 26, 2024
Lead Product(s) : Sulfur Hexafluoride
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : NaviFUS
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bevacizumab
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Notable highlights from NaviFUS at the conference include its Epilepsy neuromodulation clinical trial that just finished its safety phase, preliminary progress from its FUS combined with Avastin in rGBM patients clinical trial and other trials.
Product Name : Avastin
Product Type : Antibody
Upfront Cash : Inapplicable
November 24, 2020
Lead Product(s) : Bevacizumab
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bevacizumab
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
NaviFUS Launches Clinical Trial of a Combination FUS-Bevacizumab Therapy in rGBM Patients
Details : NaviFUS System plus bevacizumab therapy open the blood-brain barrier (BBB) and enhance bevacizumab's efficacy in patients with recurrent glioblastoma (rGBM).
Product Name : Avastin
Product Type : Antibody
Upfront Cash : Inapplicable
November 09, 2020
Lead Product(s) : Bevacizumab
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bevacizumab
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Chang Gung Memorial Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
June 24, 2020
Lead Product(s) : Bevacizumab
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Chang Gung Memorial Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable